Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ILMN Stock Forecast 2025-2026
$121.90
Current Price
$18.82B
Market Cap
Buy 8
Hold 9
Sell 3
Wall St Analyst Ratings
Distance to ILMN Price Targets
+51.8%
To High Target of $185.00
-5.7%
To Median Target of $115.00
-34.4%
To Low Target of $80.00
ILMN Price Momentum
-1.3%
1 Week Change
+26.4%
1 Month Change
-19.3%
1 Year Change
-8.8%
Year-to-Date Change
-21.9%
From 52W High of $155.99
+77.4%
From 52W Low of $68.70
📊 TOP ANALYST CALLS
Did ILMN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Illumina is one of their latest high-conviction picks.
Latest ILMN Stock Price Targets & Analyst Predictions
Based on our analysis of 35 Wall Street analysts, ILMN has a neutral consensus with a median price target of $115.00 (ranging from $80.00 to $185.00). The overall analyst rating is Buy (7.1/10). Currently trading at $121.90, the median forecast implies a -5.7% downside. This outlook is supported by 8 Buy, 9 Hold, and 3 Sell ratings.
The most optimistic forecast comes from David Westenberg at Piper Sandler, projecting a 51.8% upside. Conversely, the most conservative target is provided by Patrick Donnelly at Citigroup, suggesting a 34.4% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ILMN Analyst Ratings
8
Buy
9
Hold
3
Sell
ILMN Price Target Range
Low
$80.00
Average
$115.00
High
$185.00
Current: $121.90
Latest ILMN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ILMN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 31, 2025 | Barclays | Luke Sergott | Underweight | Maintains | $100.00 |
| Oct 31, 2025 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $142.00 |
| Oct 31, 2025 | JP Morgan | Casey Woodring | Neutral | Maintains | $105.00 |
| Oct 31, 2025 | UBS | John Sourbeer | Neutral | Maintains | $120.00 |
| Oct 31, 2025 | Canaccord Genuity | Kyle Mikson | Hold | Maintains | $112.00 |
| Oct 31, 2025 | TD Cowen | Dan Brennan | Hold | Maintains | $115.00 |
| Oct 7, 2025 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $132.00 |
| Oct 2, 2025 | Barclays | Luke Sergott | Underweight | Maintains | $95.00 |
| Aug 4, 2025 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $105.00 |
| Aug 1, 2025 | RBC Capital | Conor McNamara | Outperform | Maintains | $126.00 |
| Aug 1, 2025 | Barclays | Luke Sergott | Underweight | Maintains | $90.00 |
| Aug 1, 2025 | Canaccord Genuity | Kyle Mikson | Hold | Maintains | $105.00 |
| Jul 28, 2025 | Baird | Catherine Ramsey | Neutral | Maintains | $105.00 |
| Jul 11, 2025 | Scotiabank | Sung Ji Nam | Sector Perform | Downgrade | $125.00 |
| Jul 9, 2025 | Citigroup | Patrick Donnelly | Sell | Downgrade | $80.00 |
| Jul 8, 2025 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $128.00 |
| Jun 24, 2025 | Barclays | Luke Sergott | Underweight | Maintains | $85.00 |
| Jun 11, 2025 | Canaccord Genuity | Kyle Mikson | Hold | Maintains | $99.00 |
| May 20, 2025 | Stephens & Co. | Mason Carrico | Overweight | Reiterates | $105.00 |
| May 15, 2025 | Piper Sandler | David Westenberg | Overweight | Maintains | $185.00 |
Illumina, Inc. (ILMN) Competitors
The following stocks are similar to Illumina based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Illumina, Inc. (ILMN) Financial Data
Illumina, Inc. has a market capitalization of $18.82B with a P/E ratio of 27.3x. The company generates $4.29B in trailing twelve-month revenue with a 16.4% profit margin.
Revenue growth is +0.4% quarter-over-quarter, while maintaining an operating margin of +21.4% and return on equity of +31.2%.
Valuation Metrics
Market Cap
$18.82B
Enterprise Value
$19.92B
P/E Ratio
27.3x
PEG Ratio
-0.2x
Price/Sales
4.3x
Growth & Margins
Revenue Growth (YoY)
+0.4%
Gross Margin
+65.6%
Operating Margin
+21.4%
Net Margin
+16.4%
EPS Growth
-78.7%
Financial Health
Cash/Price Ratio
+6.9%
Current Ratio
1.4x
Debt/Equity
108.2x
ROE
+31.2%
ROA
+9.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Illumina, Inc. (ILMN) Business Model
About Illumina, Inc.
What They Do
Develops systems for genetic analysis and research.
Business Model
Illumina generates revenue through the sale of integrated systems and consumables for DNA sequencing and genetic analysis. Its products are essential for research institutions and clinical laboratories, which utilize these tools for various applications in healthcare and agriculture.
Additional Information
Headquartered in San Diego, California, Illumina is a leader in personalized medicine and plays a significant role in the advancement of genomic research. The company's innovations support critical initiatives in health, agrigenomics, and microbiology, impacting how healthcare is delivered and enhancing our understanding of complex biological systems.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
8,970
CEO
Mr. Jacob Thaysen Ph.D.
Country
United States
IPO Year
2000
Website
www.illumina.comIllumina, Inc. (ILMN) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Compared to Estimates, Illumina (ILMN) Q3 Earnings: A Look at Key Metrics
The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Oct 30, 2025
By Zacks Equity Research
Fundamental Analysis
Illumina (ILMN) Beats Q3 Earnings and Revenue Estimates
Illumina (ILMN) delivered earnings and revenue surprises of +15.52% and +1.73%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Oct 30, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
The Chinese Ministry of Commerce will lift the export ban on Illumina, Inc. (NASDAQ: ILMN) on November 10, 2025, but the company remains on the Unreliable Entities List, needing approval for purchases.
Why It Matters
The lifting of the export ban on Illumina enhances market access and potential revenue growth, but ongoing restrictions indicate regulatory risks that could impact future operations.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Illumina, Inc. held its Q3 2025 earnings call on October 30, 2025, featuring executives and analysts from various financial firms.
Why It Matters
Illumina's Q3 earnings call attracts attention from multiple analysts, indicating strong market interest and potential volatility in its stock, influencing investment strategies.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Illumina reported Q3 2025 revenue of $1.08B, flat YoY. GAAP EPS was $0.98; non-GAAP EPS was $1.34. FY 2025 revenue guidance improved, now expecting a decline of 1.5% to 0.5%.
Why It Matters
Illumina's Q3 2025 results show flat revenue but improved margins and earnings, indicating operational efficiency. Increased guidance for the fiscal year suggests potential for future growth, attracting investor interest.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Illumina Inc. (NASDAQ:ILMN) shares rose following the release of third-quarter earnings that exceeded analyst expectations.
Why It Matters
Illumina's higher-than-expected earnings suggest strong financial health, potentially boosting investor confidence and driving stock demand.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Illumina (ILMN) reported quarterly earnings of $1.34 per share, exceeding the Zacks Consensus Estimate of $1.16 and up from $1.14 per share last year.
Why It Matters
Illumina's earnings beat estimates and showed year-over-year growth, indicating strong performance and potential for stock price appreciation, attracting investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Illumina (ILMN) reported its quarterly performance for Q3 2025, highlighting key metrics that can be compared to Wall Street estimates and the previous year's results.
Why It Matters
Illumina's quarterly performance relative to Wall Street estimates and prior year results signals growth trends, impacting investor sentiment and stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About ILMN Stock
What is Illumina, Inc.'s (ILMN) stock forecast for 2026?
Based on our analysis of 35 Wall Street analysts, Illumina, Inc. (ILMN) has a median price target of $115.00. The highest price target is $185.00 and the lowest is $80.00.
Is ILMN stock a good investment in 2026?
According to current analyst ratings, ILMN has 8 Buy ratings, 9 Hold ratings, and 3 Sell ratings. The stock is currently trading at $121.90. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ILMN stock?
Wall Street analysts predict ILMN stock could reach $115.00 in the next 12 months. This represents a -5.7% decrease from the current price of $121.90. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Illumina, Inc.'s business model?
Illumina generates revenue through the sale of integrated systems and consumables for DNA sequencing and genetic analysis. Its products are essential for research institutions and clinical laboratories, which utilize these tools for various applications in healthcare and agriculture.
What is the highest forecasted price for ILMN Illumina, Inc.?
The highest price target for ILMN is $185.00 from David Westenberg at Piper Sandler, which represents a 51.8% increase from the current price of $121.90.
What is the lowest forecasted price for ILMN Illumina, Inc.?
The lowest price target for ILMN is $80.00 from Patrick Donnelly at Citigroup, which represents a -34.4% decrease from the current price of $121.90.
What is the overall ILMN consensus from analysts for Illumina, Inc.?
The overall analyst consensus for ILMN is neutral. Out of 35 Wall Street analysts, 8 rate it as Buy, 9 as Hold, and 3 as Sell, with a median price target of $115.00.
How accurate are ILMN stock price projections?
Stock price projections, including those for Illumina, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 9, 2025 1:03 PM UTC